|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FCN1 |
Gene summary for FCN1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FCN1 | Gene ID | 2219 |
| Gene name | ficolin 1 | |
| Gene Alias | FCNM | |
| Cytomap | 9q34.3 | |
| Gene Type | protein-coding | GO ID | GO:0001816 | UniProtAcc | O00602 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2219 | FCN1 | HCC1 | Human | Liver | HCC | 4.74e-17 | 1.90e+00 | 0.5336 |
| 2219 | FCN1 | HCC2 | Human | Liver | HCC | 1.90e-30 | 2.11e+00 | 0.5341 |
| 2219 | FCN1 | HCC5 | Human | Liver | HCC | 3.36e-43 | 2.46e+00 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001603222 | Liver | HCC | viral process | 286/7958 | 415/18723 | 4.41e-28 | 1.86e-25 | 286 |
| GO:001905822 | Liver | HCC | viral life cycle | 209/7958 | 317/18723 | 2.05e-17 | 2.09e-15 | 209 |
| GO:004440322 | Liver | HCC | biological process involved in symbiotic interaction | 183/7958 | 290/18723 | 9.13e-13 | 4.59e-11 | 183 |
| GO:005079212 | Liver | HCC | regulation of viral process | 109/7958 | 164/18723 | 4.52e-10 | 1.45e-08 | 109 |
| GO:005170122 | Liver | HCC | biological process involved in interaction with host | 128/7958 | 203/18723 | 2.51e-09 | 6.91e-08 | 128 |
| GO:005212612 | Liver | HCC | movement in host environment | 109/7958 | 175/18723 | 9.58e-08 | 1.89e-06 | 109 |
| GO:00022211 | Liver | HCC | pattern recognition receptor signaling pathway | 107/7958 | 172/18723 | 1.37e-07 | 2.58e-06 | 107 |
| GO:190390012 | Liver | HCC | regulation of viral life cycle | 94/7958 | 148/18723 | 1.93e-07 | 3.49e-06 | 94 |
| GO:004852511 | Liver | HCC | negative regulation of viral process | 59/7958 | 92/18723 | 2.28e-05 | 2.41e-04 | 59 |
| GO:004440912 | Liver | HCC | entry into host | 88/7958 | 151/18723 | 6.47e-05 | 5.91e-04 | 88 |
| GO:00028312 | Liver | HCC | regulation of response to biotic stimulus | 173/7958 | 327/18723 | 8.55e-05 | 7.48e-04 | 173 |
| GO:004671812 | Liver | HCC | viral entry into host cell | 83/7958 | 144/18723 | 1.73e-04 | 1.36e-03 | 83 |
| GO:004390311 | Liver | HCC | regulation of biological process involved in symbiotic interaction | 45/7958 | 72/18723 | 4.86e-04 | 3.19e-03 | 45 |
| GO:00450881 | Liver | HCC | regulation of innate immune response | 113/7958 | 218/18723 | 3.27e-03 | 1.50e-02 | 113 |
| GO:0002218 | Liver | HCC | activation of innate immune response | 32/7958 | 52/18723 | 4.35e-03 | 1.89e-02 | 32 |
| GO:19039013 | Liver | HCC | negative regulation of viral life cycle | 17/7958 | 25/18723 | 8.94e-03 | 3.45e-02 | 17 |
| GO:005237211 | Liver | HCC | modulation by symbiont of entry into host | 29/7958 | 49/18723 | 1.37e-02 | 4.86e-02 | 29 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FCN1 | SNV | Missense_Mutation | novel | c.788A>G | p.Asn263Ser | p.N263S | O00602 | protein_coding | deleterious(0.01) | probably_damaging(0.993) | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| FCN1 | SNV | Missense_Mutation | rs371244932 | c.971G>A | p.Arg324Gln | p.R324Q | O00602 | protein_coding | deleterious(0.02) | probably_damaging(0.957) | TCGA-C8-A26X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| FCN1 | SNV | Missense_Mutation | novel | c.393N>T | p.Trp131Cys | p.W131C | O00602 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A4Z1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| FCN1 | SNV | Missense_Mutation | c.944G>C | p.Ser315Thr | p.S315T | O00602 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1NE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | |
| FCN1 | SNV | Missense_Mutation | novel | c.839N>G | p.Tyr280Cys | p.Y280C | O00602 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-LL-A740-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| FCN1 | SNV | Missense_Mutation | rs768822524 | c.370C>T | p.Arg124Trp | p.R124W | O00602 | protein_coding | deleterious(0) | possibly_damaging(0.902) | TCGA-WT-AB44-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| FCN1 | SNV | Missense_Mutation | rs372958997 | c.29N>A | p.Arg10Gln | p.R10Q | O00602 | protein_coding | tolerated(0.55) | benign(0.093) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| FCN1 | SNV | Missense_Mutation | rs761901711 | c.223C>T | p.Arg75Cys | p.R75C | O00602 | protein_coding | tolerated(0.09) | benign(0.052) | TCGA-A6-3808-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| FCN1 | SNV | Missense_Mutation | novel | c.222A>T | p.Glu74Asp | p.E74D | O00602 | protein_coding | tolerated(0.11) | benign(0.071) | TCGA-A6-3808-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| FCN1 | SNV | Missense_Mutation | rs541616038 | c.614N>A | p.Arg205His | p.R205H | O00602 | protein_coding | deleterious(0.02) | possibly_damaging(0.669) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |